<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14229">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02921646</url>
  </required_header>
  <id_info>
    <org_study_id>2015-4-32-004</org_study_id>
    <nct_id>NCT02921646</nct_id>
  </id_info>
  <brief_title>Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to Chemotherapy in Patients Suffering From Pancreas Cancer</brief_title>
  <acronym>EnergiePancrea</acronym>
  <official_title>Monocentric, Prospective Study Assessing the Feasibility to Use Resting Energy Expenditure by Indirect Calorimetry as Prognostic Marker of Tumoral Response to 1st Line Chemotherapy in Patients Suffering From Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center Eugene Marquis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center Eugene Marquis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether evolution of resting energetic expenditure
      is a predictive marker of tumoral response for patients suffering from metastatic pancreatic
      cancer and treated with 1st line of chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resting energetic expenditure measurement by indirect calorimetry</measure>
    <time_frame>4 months</time_frame>
    <description>Unit measure : calorie per day</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>energetic expenditure measure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>To a standard treatment by chemotherapy, energetic expenditure will be measured 5 times during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Measure of resting energetic expenditure</intervention_name>
    <arm_group_label>energetic expenditure measure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pancreatic metastatic cancer

          -  Patient older than 18 years

          -  Initiation of a first line of chemotherapy by Folfirinox, or Gemcitabine or in
             combination with Nab-Paclitaxel.

          -  At least one measurable target lesion

          -  Patient signed consent for Energie-Pancreas study participation

        Exclusion Criteria:

          -  Other concomitant cancer

          -  Major general status alteration ( Performance status = 3 or 4 at inclusion)

          -  Concomitant diseases explaining an altered general status or having an impact on
             energetic expenditure (i.e.chronic or severe infection, severe cardiac insufficiency,
             severe respiratory insufficiency, chronic inflammatory disease, recent surgery (&lt; 1
             month), ongoing Healing, hyperthyroidism.

          -  Smoker

          -  Patient deprived of his liberty, under guardianship, curator.

          -  Pregnant patient or breastfeeding

          -  Claustrophobic patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien Edeline, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Eug√®ne Marquis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien Edeline, MD</last_name>
    <email>j.edeline@rennes.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martine Gestin, PhD</last_name>
    <phone>+ 33 2 99 25 30 36</phone>
    <email>m.gestin@rennes.unicancer.fr</email>
  </overall_contact_backup>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>December 1, 2016</lastchanged_date>
  <firstreceived_date>September 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>energetic expenditure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
